Atossa Genetics (ATOS) Competitors $0.79 +0.01 (+1.74%) Closing price 04:00 PM EasternExtended Trading$0.79 0.00 (-0.25%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. GOSS, ERAS, RGNX, AQST, YMAB, HUMA, VIGL, EOLS, CYRX, and MBXShould you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include Gossamer Bio (GOSS), Erasca (ERAS), REGENXBIO (RGNX), Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Humacyte (HUMA), Vigil Neuroscience (VIGL), Evolus (EOLS), CryoPort (CYRX), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Atossa Genetics vs. Its Competitors Gossamer Bio Erasca REGENXBIO Aquestive Therapeutics Y-mAbs Therapeutics Humacyte Vigil Neuroscience Evolus CryoPort MBX Biosciences Gossamer Bio (NASDAQ:GOSS) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability. Do institutionals & insiders have more ownership in GOSS or ATOS? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by company insiders. Comparatively, 8.7% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is GOSS or ATOS more profitable? Atossa Genetics has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Atossa Genetics' return on equity of -40.28% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-344.81% -1,774.72% -46.73% Atossa Genetics N/A -40.28%-37.10% Does the media prefer GOSS or ATOS? In the previous week, Gossamer Bio had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 10 mentions for Gossamer Bio and 9 mentions for Atossa Genetics. Gossamer Bio's average media sentiment score of 0.92 beat Atossa Genetics' score of -0.17 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, GOSS or ATOS? Gossamer Bio has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Which has better valuation and earnings, GOSS or ATOS? Atossa Genetics has lower revenue, but higher earnings than Gossamer Bio. Atossa Genetics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M3.94-$56.53M-$0.62-3.21Atossa GeneticsN/AN/A-$25.50M-$0.23-3.43 Do analysts rate GOSS or ATOS? Gossamer Bio currently has a consensus target price of $8.50, suggesting a potential upside of 327.14%. Atossa Genetics has a consensus target price of $6.17, suggesting a potential upside of 680.59%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryAtossa Genetics beats Gossamer Bio on 9 of the 16 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.04M$6.99B$5.70B$9.79BDividend YieldN/A1.32%3.77%4.10%P/E Ratio-3.4327.2230.8625.27Price / SalesN/A71.20403.8888.61Price / CashN/A22.1625.2228.45Price / Book1.394.819.516.00Net Income-$25.50M$178.31M$3.26B$265.34M7 Day Performance3.50%2.55%4.50%2.79%1 Month Performance-6.16%0.22%5.22%1.51%1 Year Performance-38.28%10.33%31.92%25.40% Atossa Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics2.6976 of 5 stars$0.79+1.7%$6.17+680.6%-39.3%$102.04MN/A-3.438Earnings ReportAnalyst RevisionGOSSGossamer Bio3.9123 of 5 stars$1.73-1.5%$8.50+390.5%+130.6%$400.19M$114.70M0.00180ERASErasca2.3776 of 5 stars$1.48+5.7%$4.57+208.9%-41.4%$396.60MN/A0.00120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpRGNXREGENXBIO4.2652 of 5 stars$7.46-5.0%$28.38+280.4%-28.0%$396.54M$83.33M-2.17370AQSTAquestive Therapeutics2.1083 of 5 stars$3.86-1.0%$10.14+162.8%-3.1%$387.38M$57.56M0.00160Earnings ReportAnalyst RevisionYMABY-mAbs Therapeutics2.6763 of 5 stars$8.52+0.1%$11.16+31.0%-30.4%$385.36M$87.68M0.00150Positive NewsHUMAHumacyte1.9632 of 5 stars$1.75-29.4%$11.71+569.4%-71.0%$384.70M$1.57M0.00150Earnings ReportAnalyst DowngradeHigh Trading VolumeVIGLVigil Neuroscience3.2872 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340EOLSEvolus3.9166 of 5 stars$5.77-2.2%$21.25+268.3%-53.1%$381.64M$266.27M0.00170CYRXCryoPort3.6257 of 5 stars$8.09+7.0%$12.00+48.3%-4.4%$379.04M$228.38M6.081,186Positive NewsMBXMBX Biosciences2.5678 of 5 stars$11.26-7.4%$37.63+234.1%N/A$376.35MN/A-2.4836 Related Companies and Tools Related Companies GOSS Alternatives ERAS Alternatives RGNX Alternatives AQST Alternatives YMAB Alternatives HUMA Alternatives VIGL Alternatives EOLS Alternatives CYRX Alternatives MBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access